MeCure Industries Plc has successfully redeemed its N3 billion Senior Secured Bond (Series 1), under its N20 billion debt issuance programme and reinforcing its financial stability and credibility in Nigeria’s capital market.

The bond, issued on May 14, 2021, as the company’s debut entry into the debt market, has now been fully repaid on schedule, underscoring the firm’s disciplined financial management and strong cash flow position.

Speaking on the development, the company’s Chief Financial Officer, Ifedamola Oluwasegun, said the redemption underscores both MeCure’s financial robustness and the confidence investors placed in the company at the point of issuance. He described the milestone as a defining moment in the firm’s capital market journey, noting that honouring the obligation as agreed reinforces trust and strengthens its reputation among institutional investors.

According to him, MeCure recorded a solid performance in 2025, driven by enhanced operational efficiency, improved cost management, and an expanded market footprint across Nigeria and key export destinations. He added that ongoing investments in manufacturing infrastructure and product innovation have continued to position the company competitively within the pharmaceutical sector.

Looking ahead, the CFO expressed optimism about the company’s outlook for 2026, citing a strong pipeline of growth opportunities expected to drive revenue expansion and support long-term value creation. He noted that the company remains focused on deepening its market presence, improving production capabilities and leveraging emerging opportunities within the healthcare value chain.

The N3 billion bond played a strategic role in funding MeCure’s expansion agenda over the past five years, supporting initiatives such as capacity upgrades, new product development, and the strengthening of its nationwide distribution network.
These investments have contributed to improved operational scale and increased market penetration.

Oluwasegun pointed out that the successful exit from its debut bond issuance positions MeCure favourably for future engagements in the capital market, particularly as investors increasingly prioritise issuers with proven track records of timely repayment and transparent financial practices.

According to him, the firm has further consolidated its standing as a disciplined and credible issuer, setting a solid foundation for potential future capital raising while continuing to pursue its growth ambitions in Nigeria’s evolving pharmaceutical landscape.